Literature DB >> 1800391

A simple non-invasive procedure for the investigation of cytochrome P-450 IIIA dependent enzymes in humans.

T Bienvenu1, E Rey, G Pons, P d'Athis, G Olive.   

Abstract

Urinary 6 beta-hydroxycortisol (6 beta OHF) is a specific marker of the induction of the cytochrome P-450 IIIA. Often, the production of 6 beta OHF is expressed from 24-h urine collection as the ratio 6 beta OHF/17-hydroxycorticosteroids or even better 6 beta OHF/free cortisol in order to adjust for minor day to day variation in adrenal cortisol production. A 24-h urine collection is a non-invasive method applicable to clinical studies in adult man, but more difficult to realize in newborn and infants. Therefore, we have tested the validity of a single urine sampling for the determination of the 6 beta OHF/free cortisol ratio as a clinical test to estimate cytochrome P-450 IIIA enzyme activity. Urinary 6 beta OHF and free cortisol have been measured in 19 healthy volunteers by high performance liquid chromatography methods using the same extraction procedure. A good correlation was found between 6 beta OHF/free cortisol ratio in morning urine samples and in 24h-collections (r = 0.899). Thus, a morning spot urine sampling is a simple procedure that may be helpful for investigations on cytochrome P-450 IIIA enzyme activity in humans, particularly in newborn and in children.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1800391

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  9 in total

1.  The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects.

Authors:  S Saima; K Furuie; H Yoshimoto; J Fukuda; T Hayashi; H Echizen
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

2.  Evaluation of 4β-Hydroxycholesterol and 25-Hydroxycholesterol as Endogenous Biomarkers of CYP3A4: Study with CYP3A-Humanized Mice.

Authors:  Shin-Ichiro Nitta; Mari Hashimoto; Yasuhiro Kazuki; Shoko Takehara; Hiraku Suzuki; Mitsuo Oshimura; Hidetaka Akita; Kan Chiba; Kaoru Kobayashi
Journal:  AAPS J       Date:  2018-04-09       Impact factor: 4.009

Review 3.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

4.  Potential inhibition of alkylating agent metabolism by fluconazole.

Authors:  S M Yule; D Walker; A D Pearson; J R Idle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-12       Impact factor: 3.267

5.  Increases in metabolism of valproate and excretion of 6beta-hydroxycortisol in patients with traumatic brain injury.

Authors:  G D Anderson; A B Awan; C A Adams; N R Temkin; H R Winn
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

6.  Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity.

Authors:  Ya-Chi Chen; S Karl Gotzkowsky; Anne N Nafziger; Robert W Kulawy; Mario L Rocci; Joseph S Bertino; Angela D M Kashuba
Journal:  Br J Clin Pharmacol       Date:  2006-08       Impact factor: 4.335

7.  Effect of the fluoroquinolone antibacterial agent DX-619 on the apparent formation and renal clearances of 6β-hydroxycortisol, an endogenous probe for CYP3A4 inhibition, in healthy subjects.

Authors:  Yuichiro Imamura; Nobuyuki Murayama; Noriko Okudaira; Atsushi Kurihara; Katsuhisa Inoue; Hiroaki Yuasa; Takashi Izumi; Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2012-10-17       Impact factor: 4.200

Review 8.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

Review 9.  Hyperforin in St. John's wort drug interactions.

Authors:  Rajanikanth Madabushi; Bruno Frank; Bernd Drewelow; Hartmut Derendorf; Veronika Butterweck
Journal:  Eur J Clin Pharmacol       Date:  2006-02-14       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.